BioSpace News Archive

Evolent Health, Inc. announced that it has entered into a definitive agreement to acquire NIA, the specialty benefit management organization owned by Centene Corporation that focuses on managing cost and quality in the areas of radiology, musculoskeletal, physical medicine, and genetics.

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”) today announced that members of its management team are scheduled to participate in the Piper Sandler 34th Annual Healthcare Conference on Wednesday, November 30, 2022.

IVERIC bio, Inc. (Nasdaq: ISEE) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for avacincaptad pegol (ACP, also known as Zimura®), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to Age-Related Macular Degeneration (AMD).

GENFIT announced the highlights from its Pipeline Day events reviewing the Company’s clinical progress and recent strategic updates.

Oklahoma Biotech Startup Programs, or OKBioStart, is one of the six initiatives that make up the Oklahoma Biotech Innovation Cluster sharing in a $35 million award from the U.S. Economic Development Association’s Build Back Better Regional Challenge.

Aidoc, the leading provider of healthcare AI solutions, today announced it has increased its FDA clearances to 11 with the addition of CT-based AI solutions - aortic dissection (AD) and all vessel occlusions (VOs).

Carmell Therapeutics announced that it has gained alignment with U.S. Food and Drug Administration (FDA) on requirements for the evaluation of the Company’s lead product, a Bone Healing Accelerant (BHA) in a second indication, foot and ankle fusion surgery.

INOVIO announced that it has agreed with its collaborator, the Coalition for Epidemic Preparedness Innovations, to discontinue development of product candidates targeting Lassa Fever and Middle East Respiratory Syndrome, following initial analyses of data from studies conducted by INOVIO and funded by CEPI.

Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 566,890 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Chief Executive Officer Michelle Keefe is scheduled to participate in a fireside chat at the 2022 Evercore ISI HealthCONx Conference on December 1, 2022, at 7:00 a.m. ET.